Treatment of atrial fibrillation associated with obesity using endothelin receptor antagonists



Atrial fibrosis prevention in obese and overweight patients


Overweight patients are at increased risk of atrial fibrillation (AF) and atrial fibrosis. Treatment of this group with endothelin receptor antagonists (ERAs) could reduce that risk and obviate the need for more invasive and expensive treatments for atrial fibrillation, such as ablation procedures. Atrial fibrillation is the most common cardiac arrhythmia and one that is increasing in prevalence – particularly among the overweight and obese. The present technology identifies the causative link between obesity and atrial fibrillation incidence, and provides a repurposed ERA drug for reducing AF in combination with a weight management programme.


Researchers at the University of Adelaide's Centre for Heart Rhythm Disorders, led by Professor Prash Sanders, have now shown that ERA-treated obese sheep have less AF induced and shorter AF periods than control obese sheep.


Intellectual property:

A PCT has been filed (PCT/AU2017/050393), which protects the use of an ERA to treat AF.  All IP rights for the method of use patent are owned by the University of Adelaide.


Partnership Opportunities:

Actively seeking a partner to work with us to deliver a clinical trial to validate the use of an ERA on obesity-induced AF.  We welcome proposals for licensing, assignment or collaboration.


Patent Information:
For Information, Contact:
Kirsten Bernhardt
The University of Adelaide
Cardiovascular Disease
Drug Delivery
Drug Development